Las Vegas Endocrinology | Henderson, NV

Research site
229 N Pecos Road, Suite 100, Henderson, Nevada, United States of America
Site insights

Top conditions

Cardiovascular Diseases (3 trials)

Atherosclerosis (3 trials)

Diabetes Mellitus (3 trials)

Type 2 Diabetes Mellitus (2 trials)

Type 1 Diabetes Mellitus (1 trial)

Top treatments


Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


4 of 7
Status: Active
Trial type: Interventional
Funder type: Industry

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Placebo in 1.5ml
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Locations recently updated

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using mul...

Active, not recruiting
Diabetes Mellitus, Type 1
Biological: Afrezza
Biological: Basal Insulin

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Dexcom logo

Dexcom (3 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems